Your request to link to rcsb for JAK1/JAK2/TYK2
- 2B7A: the structural basis of janus kinase 2 inhibition by a potent and specific pan-janus kinase inhibitor (10.1182/BLOOD-2005-06-2413 )
- 2W1I: structure determination of aurora kinase in complex with inhibitor (10.1021/JM800984V )
- 2XA4: inhibitors of jak2 kinase domain (10.1021/JM1011319 )
- 3E62: fragment based discovery of jak-2 inhibitors (10.1016/J.BMCL.2008.08.064 )
- 3E63: fragment based discovery of jak-2 inhibitors (10.1016/J.BMCL.2008.08.064 )
- 3E64: fragment based discovery of jak-2 inhibitors (10.1016/J.BMCL.2008.08.064 )
- 3EYG: crystal structures of jak1 and jak2 inhibitor complexes 10-feb-09 3eyg 1 title (10.1016/J.JMB.2009.01.041 )
- 3EYH: crystal structures of jak1 and jak2 inhibitor complexes 10-feb-09 3eyh 1 title (10.1016/J.JMB.2009.01.041 )
- 3FUP: crystal structures of jak1 and jak2 inhibitor complexes (10.1016/J.JMB.2009.01.041 )
- 3IO7: 2-aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of jak2 (10.1016/J.BMCL.2009.10.053 )
- 3IOK: 2-aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of jak2 (10.1016/J.BMCL.2009.10.053 )
- 3JY9: janus kinase 2 inhibitors (10.1021/JM901383U )
- 3KCK: a novel chemotype of kinase inhibitors (10.1016/J.BMCL.2009.11.021 )
- 3KRR: crystal structure of jak2 complexed with a potent quinoxaline atp site inhibitor (10.1158/1535-7163.MCT-10-0053 )
- 3LPB: crystal structure of jak2 complexed with a potent 2,8-diaryl- quinoxaline inhibitor (10.1016/J.BMCL.2010.02.056 )
- 3LXN: structural and thermodynamic characterization of the tyk2 and jak3 kinase domains in complex with cp-690550 and cmp-6 (10.1016/J.JMB.2010.05.020 )
- 3LXP: structural and thermodynamic characterization of the tyk2 and jak3 kinase domains in complex with cp-690550 and cmp-6 (10.1016/J.JMB.2010.05.020 )
- 3NYX: non-phosphorylated tyk2 jh1 domain with quinoline-thiadiazole- thiophene inhibitor (10.1002/PROT.22889 )
- 3NZ0: non-phosphorylated tyk2 kinase with cmp6 (10.1002/PROT.22889 )
- 3Q32: structure of janus kinase 2 with a pyrrolotriazine inhibitor (10.1016/J.BMCL.2011.01.022 )
- 3RVG: crystals structure of jak2 with a 1-amino-5h-pyrido[4,3-b]indol-4- carboxamide inhibitor (10.1021/JM200909U )
- 3TJC: co-crystal structure of jak2 with thienopyridine 8 (10.1021/JM200911R )
- 3TJD: co-crystal structure of jak2 with thienopyridine 19 (10.1021/JM200911R )
- 3UGC: structural basis of jak2 inhibition by the type ii inhibtor nvp-bbt594 (10.1158/2159-8290.CD-11-0324 )
- 3ZMM: inhibitors of jak2 kinase domain (10.1016/J.BMCL.2013.02.111 )
- 3ZON: human tyk2 pseudokinase domain bound to a kinase inhibitor
- 4AQC: triazolopyridine-based inhibitor of janus kinase 2 (10.1021/JM300248Q )
- 4BBE: aminoalkylpyrimidine inhibitor complexes with jak2 (10.1016/J.BMCL.2012.10.007 )
- 4BBF: aminoalkylpyrimidine inhibitor complexes with jak2 (10.1016/J.BMCL.2012.10.007 )
- 4C61: inhibitors of jak2 kinase domain (10.1021/JM401546N )
- 4C62: inhibitors of jak2 kinase domain (10.1021/JM401546N )
- 4D0W: pyrrole-3-carboxamides as potent and selective jak2 inhibitors (10.1016/J.BMC.2014.06.025 )
- 4D0X: pyrrole-3-carboxamides as potent and selective jak2 inhibitors (10.1016/J.BMC.2014.06.025 )
- 4D1S: pyrrole-3-carboxamides as potent and selective jak2 inhibitors (10.1016/J.BMC.2014.06.025 )
- 4E1Z: structure of mouse tyk-2 complexed to a 3-aminoindazole inhibitor (10.1186/1472-6807-12-22 )
- 4E20: structure of mouse tyk-2 complexed to a 3-aminoindazole inhibitor (10.1186/1472-6807-12-22 )
- 4E4L: jak1 kinase (jh1 domain) in complex with compound 30 (10.1021/JM300438J )
- 4E4M: jak2 kinase (jh1 domain) in complex with compound 30 (10.1021/JM300438J )
- 4E4N: jak1 kinase (jh1 domain) in complex with compound 49 (10.1021/JM300438J )
- 4E5W: jak1 kinase (jh1 domain) in complex with compound 26 (10.1021/JM300438J )
- 4E6D: jak2 kinase (jh1 domain) triple mutant in complex with compound 7 13-jun-12 4e6d 1 title (10.1021/JM300438J )
- 4E6Q: jak2 kinase (jh1 domain) triple mutant in complex with compound 12 (10.1021/JM300438J )
- 4EHZ: the jak1 kinase domain in complex with inhibitor (10.1021/JM300628C )
- 4EI4: jak1 kinase (jh1 domain) in complex with compound 20 (10.1021/JM300628C )
- 4F08: discovery and optimization of c-2 methyl imidazo-pyrrolopyridines as potent and orally bioavailable jak1 inhibitors with selectivity over jak2 (10.1021/JM300628C )
- 4F09: discovery and optimization of c-2 methyl imidazo-pyrrolopyridines as potent and orally bioavailable jak1 inhibitors with selectivity over jak2 (10.1021/JM300628C )
- 4FK6: jak1 kinase (jh1 domain) in complex with compound 72 (10.1016/J.BMCL.2012.10.008 )
- 4FVP: crystal structure of the jak2 pseudokinase domain (apo form) (10.1038/NSMB.2348 )
- 4FVQ: crystal structure of the jak2 pseudokinase domain (mg-atp-bound form) (10.1038/NSMB.2348 )
- 4FVR: crystal structure of the jak2 pseudokinase domain mutant v617f (mg- atp-bound form) (10.1038/NSMB.2348 )
- 4GFM: jak2 kinase (jh1 domain) with 2,6-dichloro-n-(2-oxo-2,5- dihydropyridin-4-yl)benzamide (10.1016/J.EJMECH.2013.03.070 )
- 4GFO: tyk2 kinase (jh1 domain) with 2,6-dichloro-n-(2-oxo-2,5- dihydropyridin-4-yl)benzamide (10.1016/J.EJMECH.2013.03.070 )
- 4GIH: tyk2 (jh1) in complex with 2,6-dichloro-n-{2-[(cyclopropylcarbonyl) amino]pyridin-4-yl}benzamide (10.1016/J.EJMECH.2013.03.070 )
- 4GII: tyk2 (jh1) in complex with 2,6-dichloro-4-cyano-n-{2- [(cyclopropylcarbonyl)amino]pyridin-4-yl}benzamide (10.1021/JM400266T )
- 4GJ2: tyk2 (jh1) in complex with 2,6-dichloro-n-[2-({[(1r,2r)-2- fluorocyclopropyl]carbonyl}amino)pyridin-4-yl]benzamide (10.1021/JM400266T )
- 4GJ3: tyk2 (jh1) in complex with 2,6-dichloro-4-cyano-n-[2-({[(1r,2r)-2- fluorocyclopropyl]carbonyl}amino)pyridin-4-yl]benzamide (10.1021/JM400266T )
- 4GL9: crystal structure of inhibitory protein socs3 in complex with jak2 kinase domain and fragment of gp130 intracellular domain (10.1038/NSMB.2519 )
- 4GMY: jak2 kinase (jh1 domain) in complex with 2,6-dichloro-n-{2- [(cyclopropylcarbonyl)amino]pyridin-4-yl}benzamide (10.1016/J.EJMECH.2013.03.070 )
- 4GVJ: tyk2 (jh1) in complex with adenosine di-phosphate (10.1016/J.EJMECH.2013.03.070 )
- 4HGE: jak2 kinase (jh1 domain) in complex with compound 8 (10.1021/JM3012239 )
- 4I5C: the jak1 kinase domain in complex with inhibitor (10.1016/J.BMCL.2013.04.018 )
- 4IVA: jak2 kinase (jh1 domain) in complex with the inhibitor trans-4-[(8as)- 2-[(1r)-1-hydroxyethyl]imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(8ah)- yl]cyclohexanecarbonitrile (10.1021/JM4004895 )
- 4IVB: jak1 kinase (jh1 domain) in complex with the inhibitor trans-4-{2- [(1r)-1-hydroxyethyl]imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6h)- yl}cyclohexanecarbonitrile (10.1021/JM4004895 )
- 4IVC: jak1 kinase (jh1 domain) in complex with the inhibitor (trans-4-{2- [(1r)-1-hydroxyethyl]imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6h)- yl}cyclohexyl)acetonitrile (10.1021/JM4004895 )
- 4IVD: jak1 kinase (jh1 domain) in complex with compound 34 (10.1021/JM4004895 )
- 4JI9: jak2 kinase (jh1 domain) in complex with tg101209 (10.1016/J.BMCL.2013.06.008 )
- 4JIA: jak2 kinase (jh1 domain) in complex with compound 9 (10.1016/J.BMCL.2013.06.008 )
- 4K6Z: the jak1 kinase domain in complex with compound 37 (10.1016/J.BMCL.2013.08.082 )
- 4K77: jak1 kinase (jh1 domain) in complex with compound 6 (10.1016/J.BMCL.2013.08.082 )
- 4L00: crystal structure of the apo jak1 pseudokinase domain (10.1038/NSMB.2673 )
- 4L01: crystal structure of the v658f apo jak1 pseudokinase domain (10.1038/NSMB.2673 )
- 4OLI: the pseudokinase/kinase protein from jak-family member tyk2 (10.1073/PNAS.1401180111 )
- 4P7E: triazolopyridine compounds as selective jak1 inhibitors: from hit identification to glpg0634 (10.1021/JM501262Q )
- 4PO6: crystal structure of the human tyk2 ferm and sh2 domains with an ifnar1 intracellular peptide
- 4PY1: crystal structure of tyk2 in complex with compound 15, 6-((2,5- dimethoxyphenyl)thio)-3-(1-methyl-1h-pyrazol-4-yl)-[1,2,4]triazolo[4, 3-b]pyridazine (10.1016/J.BMCL.2014.07.052 )
- 4WOV: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with bms-066 aka 2-methoxy-n-({6-[3-methyl-7-(methylamino)- 3,5,8,10-tetraazatricyclo[7.3.0.0, 6]dodeca-1(9),2(6),4,7,11-pentaen- 11-yl]pyridin-2-yl}methy l)acetamide (10.1074/JBC.M114.619502 )
- 4YTC: discovery of vx-509 (decernotinib): a potent and selective janus kinase (jak) 3 inhibitor for the treatment of autoimmune disease (10.1021/ACS.JMEDCHEM.5B00301 )
- 4YTF: discovery of vx-509 (decernotinib): a potent and selective janus kinase (jak) 3 inhibitor for the treatment of autoimmune diseases (10.1021/ACS.JMEDCHEM.5B00301 )
- 4YTH: discovery of vx-509 (decernotinib): a potent and selective janus kinase (jak) 3 inhibitor for the treatment of autoimmune diseases (10.1021/ACS.JMEDCHEM.5B00301 )
- 4YTI: discovery of vx-509 (decernotinib): a potent and selective janus kinase (jak) 3 inhibitor for the treatment of autoimmune disease (10.1021/ACS.JMEDCHEM.5B00301 )
- 4Z32: crystal structure of the ferm-sh2 domains of jak2 (10.1371/JOURNAL.PONE.0156218 )
- 4ZIM: crystal structure of janus kinase 2 in complex with a 9h-carbazole-1- carboxamide inhibitor (10.1016/J.BMCL.2015.04.101 )
- 5AEP: novel pyrrole carboxamide inhibitors of jak2 as potential treatment of myeloproliferative disorders (10.1016/J.BMC.2015.03.059 )
- 5C01: crystal structure of kinase (10.1074/JBC.M115.672048 )
- 5C03: crystal structure of kinase (10.1074/JBC.M115.672048 )
- 5CF4: crystal structure of janus kinase 2 in complex with n,n-dicyclopropyl- 10-ethyl-7-[(3-methoxypropyl)amino] -3-methyl-3,5,8,10- tetraazatricyclo[7.3.0.0,6] dodeca-1(9),2(6),4,7,11-pentaene-11- carboxamide (10.1021/ACSMEDCHEMLETT.5B00225 )
- 5CF5: crystal structure of janus kinase 2 in complex with n,n-dicyclopropyl- 7-[(dimethyl-1,3-thiazol-2-yl)amino]-10-ethyl-3-methyl-3,5,8,10- tetraazatricyclo[7.3.0.02,6] dodeca-1(9),2(6),4,7,11-pentaene-11- carboxamide (10.1021/ACSMEDCHEMLETT.5B00225 )
- 5CF6: crystal structure of janus kinase 2 in complex with n,n-dicyclopropyl- 10-[(2s)-2,3-dihydroxypropyl]-3-methyl-7-(methylamino)-3,5,8,10- tetraazatricyclo [7.3.0.02,6]dodeca-1(9),2(6),4,7,11-pentaene-11- carboxamide (10.1021/ACSMEDCHEMLETT.5B00225 )
- 5CF8: crystal structure of janus kinase 2 in complex with n,n-dicyclopropyl- 10-ethyl-7-[(3-methoxypropyl)amino] -3-methyl-3,5,8,10- tetraazatricyclo[7.3.0.0,6] dodeca-1(9),2(6),4,7,11-pentaene-11- carboxamide (10.1021/ACSMEDCHEMLETT.5B00226 )
- 5E1E: human jak1 kinase in complex with compound 30 at 2.30 angstroms resolution (10.1016/J.BMCL.2015.11.031 )
- 5F1Z: structure of tyk2 with inhibitor 16: 3-azanyl-5-[(2~{s})-3- methylbutan-2-yl]-7-[1-methyl-5-(2-oxidanylpropan-2-yl)pyrazol-3-yl]- 1~{h}-pyrazolo[4,3-c]pyridin-4-one (10.1021/ACS.JMEDCHEM.5B01857 )
- 5F20: structure of tyk2 with inhibitor 4: 3-azanyl-5-(2-methylphenyl)-7-(1- methylpyrazol-3-yl)-1~{h}-pyrazolo[4,3-c]pyridin-4-one (10.1021/ACS.JMEDCHEM.5B01857 )
- 5HEZ: jak2 kinase (jh1 domain) mutant p1057a in complex with tg101209 (10.1126/SCITRANSLMED.AAG1974 )
- 5HX8: jak1 complex with 4-[(4-aminocyclohexyl)amino]-3-(1h-benzimidazol-2- yl)-1h-pyridin-2-one (10.1016/J.BMCL.2016.02.035 )
- 5I4N: crystal structure of the e596a v617f mutant jak2 pseudokinase domain bound to mg-atp (10.1042/BCJ20160085 )
- 5IXD: structure of human jak1 ferm/sh2 in complex with ifn lambda receptor (10.1016/J.STR.2016.03.023 )
- 5IXI: structure of human jak1 ferm/sh2 in complex with ifnlr1/il10ra chimera (10.1016/J.STR.2016.03.023 )
- 5KHW: crystal structure of jak1 in complex with adp (10.1107/S2053230X16016356 )
- 5KHX: crystal structure of jak1 in complex with pf-4950736 (10.1107/S2053230X16016356 )
- 5L04: structure of interferon lambda 1 receptor with human kinase jak1 (10.1016/J.JMB.2016.10.005 )
- 5L3A: fragment-based discovery of 6-arylindazole jak inhibitors (10.1021/ACSMEDCHEMLETT.6B00087 )
- 5TKD: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with 6-[(3,5-dimethylphe nyl)amino]-8- (methylamino) imidazo[1,2-b]pyridazine-3-carbo xamide (10.1039/C6MD00560H )
- 5TQ3: design and synthesis of a pan-jak kinase inhibitor clinical candidate (pf-06263276) suitable for the treatment of inflammatory diseases of the lungs and skin (10.1021/ACS.JMEDCHEM.6B01634 )
- 5TQ4: design and synthesis of a pan-jak kinase inhibitor clinical candidate (pf-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin (10.1021/ACS.JMEDCHEM.6B01634 )
- 5TQ5: design and synthesis of a pan-jak kinase inhibitor clinical candidate (pf-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin (10.1021/ACS.JMEDCHEM.6B01634 )
- 5TQ6: design and synthesis of a pan-jak kinase inhibitor clinical candidate (pf-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin (10.1021/ACS.JMEDCHEM.6B01634 )
- 5TQ7: design and synthesis of a pan-jak kinase inhibitor clinical candidate (pf-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin (10.1021/ACS.JMEDCHEM.6B01634 )
- 5TQ8: design and synthesis of a pan-jak kinase inhibitor clinical candidate (pf-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin (10.1021/ACS.JMEDCHEM.6B01634 )
- 5USY: jak2 jh1 in complex with jnj-7706621 (10.1021/ACSMEDCHEMLETT.7B00153 )
- 5USZ: jak2 jh2 in complex with jnj-7706621 (10.1021/ACSMEDCHEMLETT.7B00153 )
- 5UT0: jak2 jh2 in complex with at9283 (10.1021/ACSMEDCHEMLETT.7B00153 )
- 5UT1: jak2 jh2 in complex with bi-d1870 (10.1021/ACSMEDCHEMLETT.7B00153 )
- 5UT2: jak2 jh2 in complex with prt062607 (10.1021/ACSMEDCHEMLETT.7B00153 )
- 5UT3: jak2 jh2 in complex with ikk-2 inhibitor vi (10.1021/ACSMEDCHEMLETT.7B00153 )
- 5UT4: jak2 jh2 in complex with nvp-bsk805 (10.1021/ACSMEDCHEMLETT.7B00154 )
- 5UT5: jak2 jh2 in complex with glpg0634 (10.1021/ACSMEDCHEMLETT.7B00154 )
- 5UT6: jak2 jh2 in complex with a diaminopyrimidine (10.1021/ACSMEDCHEMLETT.7B00154 )
- 5WAL: identification of an imidazopyridine scaffold to generate potent and selective tyk2 inhibitors that demonstrate activity in an in vivo psoriasis model (10.1016/J.BMCL.2017.08.022 )
- 5WEV: identification of an imidazopyridine scaffold to generate potent and selective tyk2 inhibitors that demonstrate activity in an in vivo psoriasis model (10.1016/J.BMCL.2017.08.022 )
- 5WIJ: jak2 pseudokinase in complex with nu6140 (10.1021/ACSCHEMBIO.8B00722 )
- 5WIK: jak2 pseudokinase in complex with bi-d1870 (10.1021/ACSCHEMBIO.8B00722 )
- 5WIL: jak2 pseudokinase in complex with azd7762 (10.1021/ACSCHEMBIO.8B00722 )
- 5WIM: jak2 pseudokinase in complex with at9283 (10.1021/ACSCHEMBIO.8B00722 )
- 5WIN: jak2 pseudokinase in complex with jnj7706621 (10.1021/ACSCHEMBIO.8B00722 )
- 5WO4: jak1 complexed with compound 28 (10.1021/ACS.JMEDCHEM.7B01135 )
- 6AAH: crystal structure of jak1 in complex with peficitinib (10.1016/J.BMC.2018.08.005 )
- 6AAJ: crystal structure of jak2 in complex with peficitinib (10.1016/J.BMC.2018.08.005 )
- 6AAM: crystal structure of tyk2 in complex with peficitinib (10.1016/J.BMC.2018.08.005 )
- 6BBU: crystal structure of jak1 in complex with compound 25 (10.1021/ACS.JMEDCHEM.7B01598 )
- 6BBV: crystal structure of jak2 in complex with compound 25 (10.1021/ACS.JMEDCHEM.7B01598 )
- 6BRW: jak2 jh2 in complex with xmu-mp-1
- 6BS0: jak2 jh2 in complex with 63552444
- 6BSS: jak2 jh2 in complex with nu6102
- 6C7Y: crystal structure of inhibitory protein socs1 in complex with jak1 kinase domain (10.1038/S41467-018-04013-1 )
- 6D2I: jak2 pseudokinase v617f in complex with at9283 (10.1021/ACSCHEMBIO.8B00722 )
- 6DBK: tyk2 with compound 8 (10.1021/ACS.JMEDCHEM.8B00917 )
- 6DBM: tyk2 with compound 23 (10.1021/ACS.JMEDCHEM.8B00917 )
- 6DBN: jak1 with compound 23 (10.1021/ACS.JMEDCHEM.8B00917 )
- 6DRW: jak2 jh1 in complex with jnj-7706621 (crystal form 2)
- 6E2P: structure of human jak2 ferm/sh2 in complex with leptin receptor (10.7554/ELIFE.38089 )
- 6E2Q: structure of human jak2 ferm/sh2 in complex with erythropoietin receptor (10.7554/ELIFE.38089 )
- 6ELR: human jak1 kinase domain in complex with compound 7
- 6G3C: crystal structure of jak2-v617f pseudokinase domain in complex with compound 2 (10.1021/ACSCHEMBIO.8B00722 )
- 6GGH: human jak1 kinase domain in complex with inhibitor
- 6HZU: human jak1 in complex with lasw1393 (10.1021/ACS.JMEDCHEM.9B00533 )
- 6M9H: jak2 jh2 in complex with diaminopyrimidine jak040
- 6N77: structure of the human jak1 kinase domain with compound 15 (10.1016/J.BMCL.2019.04.008 )
- 6N78: structure of the human jak1 kinase domain with compound 21 (10.1016/J.BMCL.2019.04.008 )
- 6N79: structure of the human jak1 kinase domain with compound 20 (10.1016/J.BMCL.2019.04.008 )
- 6N7A: structure of the human jak1 kinase domain with compound 39 (10.1016/J.BMCL.2019.04.008 )
- 6N7B: structure of the human jak1 kinase domain with compound 38 (10.1016/J.BMCL.2019.04.008 )
- 6N7C: structure of the human jak1 kinase domain with compound 56 (10.1016/J.BMCL.2019.04.008 )
- 6N7D: structure of the human jak1 kinase domain with compound 54 (10.1016/J.BMCL.2019.04.008 )
- 6NSL: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound-6c aka 6-((1-(4-cyanopheny l)-2-oxo-1,2- dihydro-3-pyridinyl)amino)-n-cyclopropyl-8-(m ethylamino)imidazo[1,2- b]pyridazine-3-carboxamide (10.1021/ACSMEDCHEMLETT.9B00035 )
- 6NZE: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound_5 aka 4-[(2-carbamoylphen yl)amino]-6-[(5- fluoropyridin-2-yl)amino]-n-methylpyridine -3-carboxamide (10.1021/ACS.JMEDCHEM.9B00443 )
- 6NZF: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound_5 aka 4-[(2-carbamoylphen yl)amino]-6-[(5- fluoropyridin-2-yl)amino]-n-methylpyridine -3-carboxamide (10.1021/ACS.JMEDCHEM.9B00443 )
- 6NZH: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound_40 aka 6-cyclopropaneamido-4-[(2- methanesulfonylphenyl)amino]-n-methylpyridine-3-carboxamide (10.1021/ACS.JMEDCHEM.9B00443 )
- 6NZP: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound-11 aka 6-cyclopropaneamido-4-{[2-methoxy-3- (1-methyl-1h-1,2,4-tri azol-3-yl)phenyl]amino}-n-(?h?) methylpyridazine-3-carboxamide (10.1021/ACS.JMEDCHEM.9B00444 )
- 6NZQ: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound_29 aka 6-[(5-fluoro-4-meth ylpyridin-2-yl) amino]-4-({2-methoxy-3-[(pyridin-2-ylmethyl )carbamoyl]phenyl}amino)- n-methylpyridine-3-carboxamide (10.1021/ACS.JMEDCHEM.9B00444 )
- 6NZR: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound_12 aka 4-[(2-methanesulfonylphenyl)amino]-n- (h3)methyl-6-[(pyridin-2- yl)amino]pyridazine-3-carboxamide (10.1021/ACS.JMEDCHEM.9B00444 )
- 6OAV: jak2 jh2 in complex with jak146 (10.1021/ACS.JMEDCHEM.0C00192 )
- 6OBB: jak2 jh2 in complex with jak170 (10.1021/ACS.JMEDCHEM.0C00192 )
- 6OBF: jak2 jh2 in complex with jak179 (10.1021/ACS.JMEDCHEM.0C00192 )
- 6OBL: jak2 jh2 in complex with jak168 (10.1021/ACS.JMEDCHEM.0C00192 )
- 6OCC: jak2 jh2 in complex with jak190 (10.1021/ACS.JMEDCHEM.0C00192 )
- 6OVA: crystal structure of tyk2 with novel pyrrolidinone inhibitor (10.1016/J.BMCL.2020.126963 )
- 6RSB: structure based optimization of jak1-atp binding pocket inhibitors in the aminopyrazole class
- 6RSC: structure based optimization of jak1-atp binding pocket inhibitors in the aminopyrazole class
- 6RSD: structure based optimization of jak1-atp binding pocket inhibitors in the aminopyrazole class
- 6RSE: structure based optimization of jak1-atp binding pocket inhibitors in the aminopyrazole class
- 6RSH: structure based optimization of jak1-atp binding pocket inhibitors in the aminopyrazole class
- 6SM8: human jak1 kinase domain in complex with inhibitor (10.1021/ACS.JMEDCHEM.9B01392 )
- 6SMB: human jak1 kinase domain in complex with inhibitor (10.1021/ACS.JMEDCHEM.9B01392 )
- 6TPD: fragment-based discovery of pyrazolopyridones as jak1 inhibitors with excellent subtype selectivity (10.1021/ACS.JMEDCHEM.0C00359 )
- 6TPE: fragment-based discovery of pyrazolopyridones as jak1 inhibitors with excellent subtype selectivity (10.1021/ACS.JMEDCHEM.0C00359 )
- 6TPF: fragment-based discovery of pyrazolopyridones as jak1 inhibitors with excellent subtype selectivity (10.1021/ACS.JMEDCHEM.0C00359 )
- 6VGL: jak2 jh1 in complex with ruxolitinib (10.1021/ACS.JMEDCHEM.0C01952 )
- 6VN8: jak2 jh1 in complex with baricitinib (10.1021/ACS.JMEDCHEM.0C01952 )
- 6VNB: jak2 jh1 in complex with bl2-084 (10.1021/ACS.JMEDCHEM.0C01952 )
- 6VNC: jak2 jh1 in complex with bl2-096 (10.1021/ACS.JMEDCHEM.0C01952 )
- 6VNE: jak2 jh1 in complex with fedratinib (10.1021/ACS.JMEDCHEM.0C01952 )
- 6VNF: jak2 jh1 in complex with ma9-086 (10.1021/ACS.JMEDCHEM.0C01952 )
- 6VNG: jak2 jh1 in complex with pn2-118 (10.1021/ACS.JMEDCHEM.0C01952 )
- 6VNH: jak2 jh1 in complex with pn2-123 (10.1021/ACS.JMEDCHEM.0C01952 )
- 6VNI: jak2 jh1 in complex with pn3-115 (10.1021/ACS.JMEDCHEM.0C01952 )
- 6VNJ: jak2 jh1 in complex with pn4-014 (10.1021/ACS.JMEDCHEM.0C01952 )
- 6VNK: jak2 jh1 in complex with pn4-073 (10.1021/ACS.JMEDCHEM.0C01952 )
- 6VNL: jak2 jh1 in complex with sg3-179 (10.1021/ACS.JMEDCHEM.0C01952 )
- 6VNM: jak2 jh1 in complex with sy5-103 (10.1021/ACS.JMEDCHEM.0C01952 )
- 6VNS: crystal structure of tyk2 kinase with compound 13 (10.1016/J.BMC.2020.115481 )
- 6VNV: crystal structure of tyk2 kinase with compound 14 (10.1016/J.BMC.2020.115481 )
- 6VNX: crystal structure of tyk2 kinase with compound 19 (10.1016/J.BMC.2020.115481 )
- 6VNY: crystal structure of tyk2 kinase with compound 10 (10.1016/J.BMC.2020.115481 )
- 6VS3: jak2 jh1 in complex with bl2-057 (10.1021/ACS.JMEDCHEM.0C01952 )
- 6VSN: jak2 jh1 in complex with bl2-110 (10.1021/ACS.JMEDCHEM.0C01952 )
- 6W8L: crystal structure of jak1 kinase with compound 10 (10.1016/J.BMC.2020.115481 )
- 6WTN: human jak2 jh1 domain in complex with ruxolitinib
- 6WTO: human jak2 jh1 domain in complex with baricitinib
- 6WTP: human jak2 jh1 domain in complex with protac-intermediate linker handle 3
- 6WTQ: human jak2 jh1 domain in complex with protac-intermediate linker handle 4
- 6X8E: crystal structure of jak2 with compound 11 (10.1021/ACS.JMEDCHEM.0C00948 )
- 6X8F: crystal structure of tyk2 with compound 11 (10.1021/ACS.JMEDCHEM.0C00948 )
- 6X8G: crystal structure of tyk2 with compound 22 (10.1021/ACS.JMEDCHEM.0C00948 )
- 6XJK: jak2 jh2 in complex with jak067 (10.1021/ACS.JCTC.0C00847 )
- 7AX4: human tyk2 pseudokinase domain (575-869) in complex with 5-(4-fluoro- phenyl)-2-ureido-thiophene-3-carboxylic acid amide (10.1177/24725552211002472 )
- 7JYO: jak2 jh2 in complex with jak064
- 7JYQ: jak2 jh2 in complex with jak020
- 7K7O: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound-12 aka:6-[(cyclopropanecarbonyl)amino]-4-{[2- methoxy-3-(pyrimidin-2-yl)phenyl]amino}-n-methylpyridazine-3- carboxamide (10.1021/ACS.JMEDCHEM.0C01698 )
- 7K7Q: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound-12 aka:6-[(cyclopropanecarbonyl)amino]-4-({3- [6-(dimethylcarbamoyl)pyridazin-3-yl]-2-methoxyphenyl}amino)-n- methylpyridazine-3-carboxamide (10.1021/ACS.JMEDCHEM.0C01698 )